MYELODYSPLASTIC SYNDROMES

This study tests whether alternating two different drug combinations can help control higher-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) in adults who have not responded to standard treatments. Participants will receive cycles of cladribine, low-…

This study tests an experimental drug called elritercept (KER-050) in about 160 adults with a bone marrow disorder called myelodysplastic syndromes (MDS) who have anemia. The main goal is to check the drug's safety and find the best dose. Researchers will also see if it helps the…

This study is for people with serious blood cancers, immune deficiencies, or genetic disorders who need a stem cell transplant. Researchers are using umbilical cord blood from unrelated donors to see how well the new cells take hold and rebuild healthy blood counts. The goal is t…

This study tests whether giving hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) before a stem cell transplant is safe and can improve recovery. It involves adults with certain blood cancers like acute myeloid leukemia or myelofibrosis. The goal is to se…

This early-phase study tests a new treatment for adults with acute myeloid leukemia or myelodysplastic syndrome who still have small amounts of cancer cells after standard therapy. The treatment uses the patient's own blood cells that are specially armed with a protein to help th…

This study looks at whether getting a stem cell transplant right away is as good as getting other treatments first and then the transplant for people with high-risk myelodysplastic syndrome (MDS). About 236 adults will be randomly assigned to one of two groups. The goal is to see…

This study is testing whether a cord blood transplant can help children and young adults (up to age 26) with blood cancers like leukemia and lymphoma. The treatment uses donated cord blood to replace damaged bone marrow. The main goal is to see how many patients remain cancer-fre…

This study tests whether adding a protein called interferon-γ to donor immune cells can help control acute myeloid leukemia or myelodysplastic syndromes that have come back after a stem cell transplant. About 45 adults will receive this combination to see if it improves survival …

This study tests a drug called pacritinib for people aged 12 and older with myelodysplastic syndromes (MDS) or related blood disorders. The goal is to find the best dose and see if it helps control the disease. Participants take capsules twice daily for up to 8 years, with regula…

This early-stage study tests a specially engineered donor stem cell product called Orca-Q in 300 people with blood cancers like leukemia or myelodysplastic syndromes who need a stem cell transplant. The goal is to see if it is safe and helps the body accept the new cells without …

This study tests a new way of giving two approved drugs (5-azacitidine and decitabine) to people with myelodysplastic syndromes (MDS) or related bone marrow disorders. Instead of standard high doses, the drugs are given in a low-dose, alternating schedule to reduce side effects a…

This study tests whether adding venetoclax to standard chemotherapy before a stem cell transplant can help prevent cancer from coming back in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). About 138 participants aged 12 to 60 will be random…

This study tests an experimental drug called CTX-712 in adults with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have come back or not responded to prior treatments. The goal is to find a safe dose and see if the drug can shrink or control the cancer. Abou…

This study is testing whether statins, a common cholesterol-lowering drug, can help people with early blood disorders called CCUS and lower-risk MDS. These conditions can progress to more serious blood cancers or cause heart problems, and there are no approved treatments to impro…

This early-phase study tests a new treatment called MNV-201 for people with low-risk myelodysplastic syndrome (MDS), a bone marrow disorder that causes low blood counts. The therapy uses the patient's own blood stem cells enriched with mitochondria from donated placentas to impro…

This study looks at how the cancer drug ASTX727 (decitabine and cedazuridine) is processed by the body in people with severe kidney problems compared to those with normal kidneys. It involves 18 adults with certain blood cancers or solid tumors. The goal is to understand safety a…

This early-stage study tests a new drug called MGD024 in about 130 adults with certain blood cancers (like leukemia or lymphoma) that came back or didn't get better with standard treatments. The main goal is to find the safest dose and understand side effects. Participants receiv…

This study tests whether giving the drug DEC-C early can help people with myelodysplastic syndromes (MDS) who still have small amounts of cancer after a stem cell transplant. About 209 participants will be checked for leftover cancer cells using a special blood test. Those with d…

This early-phase trial tests whether giving special immune cells (CIML NK cells) along with a drug called IL-2 can safely prevent leukemia or related blood cancers from coming back after a stem cell transplant. About 15 adults with high-risk acute myeloid leukemia, myelodysplasti…

This study is for people with blood cancers like AML or MDS. It tests a stem cell transplant using a milder chemo combination (treosulfan and fludarabine) followed by drugs to prevent graft-versus-host disease. The goal is to see if this approach improves survival at 100 days and…

This study tests whether adding a specific type of donor cell (CD45RA-depleted) can help children recover their immune system faster after a stem cell transplant for blood cancers. The goal is to lower the risk of serious viral or fungal infections without increasing graft-versus…

This early-phase study tests a drug called danvatirsen, first alone and then combined with venetoclax, in 38 adults whose acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) have not responded to or returned after standard treatments. The main goal is to see if the tr…

This study tests whether a new way of giving three drugs (ATG, tacrolimus, and methotrexate) can prevent a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers like leukemia. About 29 adults aged 18-60 who have a matched dono…

This study tests a combination of two drugs, luspatercept and EPO, for people with a low-risk form of myelodysplastic syndrome (MDS) who did not get better with standard EPO treatment alone. The goal is to find the best dose and see if the combo works better than luspatercept by …

This study compares two approaches to prevent graft-versus-host disease (GVHD) in 400 people receiving stem cell transplants from unrelated donors for blood cancers like leukemia and lymphoma. One method uses a drug called thymoglobulin, while the other uses a combination of calc…

This early-phase study tests whether specially engineered donor immune cells (TSC-100 or TSC-101) can safely prevent blood cancers like AML, MDS, or ALL from coming back after a stem cell transplant. About 75 adults will receive either the engineered cells or standard care. The m…

This study tests an experimental drug called elritercept in adults with a bone marrow disorder (MDS) who need regular red blood cell transfusions. The main goal is to see if the drug can help patients go without transfusions for at least 8 weeks. About 225 participants will recei…

This study tests a lower, weekly dose of two approved drugs (decitabine and venetoclax) for people with bone marrow cancers like MDS, AML, and CMML. The goal is to see if this gentler schedule can keep patients on treatment longer with fewer interruptions. About 91 adults aged 18…

This program offers galinpepimut-S, an experimental immune therapy, to individual patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have run out of standard treatments. It is not a cure but aims to help control the disease. Only patients with no sui…

This study tests a treatment called Orca-T for people with acute myeloid leukemia or myelodysplastic syndrome. Orca-T is made from a donor's blood cells and given after a stem cell transplant. The goal is to see if it can help patients live longer without the cancer coming back a…

This study tests an experimental drug called DISC-0974 in about 150 adults with myelofibrosis or myelodysplastic syndrome (MDS) who also have anemia. The goal is to see if the drug is safe and can reduce the need for blood transfusions or raise hemoglobin levels. The trial is in …

This study tests a drug called olutasidenib in people with specific blood conditions (CCUS, lower-risk MDS, or CMML) that have an IDH1 mutation. The goal is to see if the drug can help control the disease and to check for side effects. About 15 participants will take part in this…

This study tests whether adding high-dose vitamin C to a standard chemotherapy drug (azacitidine) can help adults with a serious bone marrow disorder called myelodysplastic syndrome (MDS). About 38 people with higher-risk MDS will receive the combination intravenously. The goal i…

This study tests a drug called luspatercept in 40 adults with lower-risk myelodysplastic syndromes (MDS), a bone marrow condition that often requires frequent blood transfusions. The goal is to see if luspatercept can reduce the number of transfusions needed. Participants will re…

This early-stage study tests an experimental pill, BH-30236, in adults whose acute myeloid leukemia or high-risk myelodysplastic syndrome has returned or not responded to prior therapy. The study first finds a safe dose, then tests the drug alone or with another medicine (venetoc…

This early-stage study is testing a new drug called SX-682, alone or with a standard chemotherapy (decitabine), for people with myelodysplastic syndrome (MDS), a type of bone marrow cancer. The main goal is to find the safest dose and identify side effects. About 151 adults with …

This study is for adults with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who have had a stem cell transplant from a half-matched donor. After the transplant, participants receive extra immune cells called natural killer (NK) cells from the same donor to try t…

This study tests an oral drug (ASTX030) that combines two medicines to treat certain blood cancers like myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). About 316 adults will take the pill alone or with another drug (venetoclax) to see if it works as well as the …

This early-phase study tests whether adding an experimental drug (defactinib) to an approved oral treatment (decitabine/cedazuridine) is safe and tolerable for people with high-risk myelodysplastic syndromes, certain acute myeloid leukemias, and chronic myelomonocytic leukemia. A…

This study tests whether using two different stem cell donors together can improve survival for people with certain blood cancers like leukemia and myelodysplastic syndromes. About 36 participants will receive a transplant from a half-matched family donor plus umbilical cord bloo…

This study tests a new drug called AND017 for anemia in people with lower-risk myelodysplastic syndromes (MDS). The goal is to see if it can raise hemoglobin levels or reduce the need for blood transfusions. About 63 adults with low transfusion needs will receive different doses …

This study looks at how the cancer drug ASTX727 behaves in people with liver problems. It includes 27 adults with blood cancers or solid tumors who have moderate or severe liver issues. The goal is to find safe and effective doses for these patients.

This early-phase study tests whether adding the drug momelotinib to standard treatment (azacitidine) can better control certain rare blood cancers like chronic myelomonocytic leukemia and chronic neutrophilic leukemia. About 18 adults will take the combination for up to 24 months…

This study tests whether giving two drugs (decitabine and filgrastim) after a stem cell transplant can safely prevent the cancer from coming back in children and young adults with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or similar blood cancers. About 37 pa…

This study tests a treatment for people with myelodysplastic syndromes (MDS), a bone marrow disorder. It combines a drug called venetoclax with a chemotherapy-like agent and an infusion of immune cells from a partially matched donor. The goal is to control the disease and improve…

This study tests a new experimental drug called EP0042 in adults with advanced blood cancers like acute myeloid leukemia (AML). The goal is to find a safe dose that might work against the cancer, either alone or with other treatments. About 70 participants will be enrolled to che…

This study tests a drug called momelotinib in 80 adults with low-risk myelodysplastic syndromes (MDS) who have anemia. The goal is to see if the drug can help patients go without red blood cell transfusions for at least 12 weeks. The study has two parts: first, finding the best d…

This early-phase study tests a new way to do a stem cell transplant for people with aggressive or returning acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The method uses specially selected donor cells to try to prevent graft-versus-host disease without needing …

This study tests a new drug called BGB-11417 for people with certain blood cancers like acute myeloid leukemia and myelodysplastic syndromes. The goal is to find a safe dose and see if the drug can shrink or control the cancer. About 260 adults will take the drug alone or with an…

This early-phase study tests a new automated method (CliniMACS Prodigy) to select CD34 stem cells for patients with blood cancers who need a stem cell boost or second transplant. The goal is to reduce the risk of severe graft-versus-host disease (GVHD) while improving blood cell …

This study tests whether a tailored exercise program plus a vitamin-like supplement (NAD+ precursor) can improve muscle mass, strength, and fitness in adolescents and young adults who had a bone marrow transplant for leukemia or other blood disorders. About 80 participants will b…

This early-phase study tests whether giving patients extra immune cells (gamma delta T-cells) after a partially matched bone marrow transplant can help kill cancer cells and lower the risk of graft-versus-host disease. About 38 adults with leukemia or myelodysplastic syndromes wi…

This early-stage study tests a new oral drug, GLB-001, in about 48 adults whose acute myeloid leukemia or high-risk myelodysplastic syndromes have returned or stopped responding to treatment. The main goals are to check safety, find the best dose, and see if the drug shows any si…

This early-phase study tests whether adding venetoclax to standard chemotherapy is safe and effective for adults newly diagnosed with acute myeloid leukemia (AML) or advanced myelodysplastic syndrome (MDS). About 99 participants will receive different doses of venetoclax alongsid…

This study tests an experimental drug called enzomenib (DSP-5336) in people with acute leukemia and certain other blood cancers. The goal is to find a safe dose and see if the drug can shrink or control the cancer. About 606 adults will take part, and the study is currently recru…

This study tests a special stem cell transplant that removes certain immune cells to lower the risk of graft-versus-host disease (GVHD) and reduce the need for long-term immune-suppressing drugs. It includes up to 48 people with inherited bone marrow failure disorders like Fancon…

This early-phase trial tests whether adding Decitabine and Venetoclax to a standard reduced-intensity stem cell transplant is safe for people with high-risk myeloid cancers like acute myeloid leukemia. About 20 adults aged 18-75 with a matched donor will receive the drug combo al…

This early-phase trial tests a special type of immune cell (CIML NK cells) combined with a low dose of IL-2 in people whose blood cancer (AML, MDS, MPN, or JMML) has returned after a stem cell transplant. The main goal is to find the safest dose and see if it can put the cancer b…

This early-phase study tests a new drug called iadademstat combined with a standard chemotherapy (azacitidine) for people with myelodysplastic syndrome (MDS), a bone marrow disorder. The main goal is to find the safest dose of iadademstat for future studies. About 12 adults with …

This early-stage trial tests a cell therapy called Orca-T combined with standard drugs to prevent graft-versus-host disease (GVHD) in up to 24 adults with advanced blood cancers like leukemia or MDS. Participants receive a stem cell transplant from a donor who is only a 7 out of …

This study tests a combination of two drugs, leflunomide and decitabine, in 26 adults with myelodysplastic syndromes (MDS) that returned or didn't respond to prior treatment. The goal is to find safe and effective doses to control the disease. Participants receive decitabine by I…

This study tests whether giving blood transfusions at home is practical and acceptable for cancer patients who need regular blood products. About 30 adults with blood cancers or bone marrow failure who require at least two transfusions per month will receive 1-5 units of blood at…

This study tests a new program that gives blood transfusions at home to people with advanced blood cancers who are in hospice care. The goal is to see if this improves quality of life, mood, and reduces hospital visits near the end of life. About 700 adults with relapsed or hard-…

This study tests whether tranexamic acid (TXA), a drug that helps blood clots stay in place, can reduce bleeding in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). About 75 adults with these blood cancers who have low platelet counts will be randomly …

This study aims to find genetic changes in people with early-stage blood cancers or conditions that may lead to cancer. Researchers will analyze blood, bone marrow, or cheek cell samples from up to 10,000 participants to understand how these diseases progress. The goal is to impr…

This study collects blood, bone marrow, and tissue samples from up to 15,000 people with blood cancers or related disorders. The samples are stored in a central bank for researchers to use in future studies. Participants do not receive any treatment as part of this study. The goa…

This study collects blood, bone marrow, and other samples from up to 1,716 people with non-cancerous blood diseases and their family members. Researchers will analyze genes to find causes of these diseases and why some people get sicker than others. The goal is to improve future …

This study tests a telehealth program that helps older adults (60+) with blood cancers like leukemia and MDS talk with their doctors about their care goals. The program aims to improve communication, reduce anxiety, and help patients complete advance directives. About 207 patient…

This study looks at whether checking for a specific type of stem cell in people with myelodysplastic syndromes (MDS) can better predict if their disease will come back after a stem cell transplant. Researchers will use a special lab test to measure these stem cells before and aft…

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with clinical trials they might be eligible for. Researchers will enroll up to 50,000 people with various types of cancer to see if the AI increases trial enrollment and to identify …

This study follows people with inherited gene changes (DDX41) that raise the risk of blood cancers like MDS and AML. Researchers will collect health information, blood, and tissue samples over 10 years to understand how these gene changes lead to cancer. No treatment is given; th…

This study looks at how services from Blood Cancer United (formerly The Leukemia & Lymphoma Society) affect people with blood cancers like leukemia, lymphoma, and myeloma. Researchers will track 400 patients over time to see if the organization helps with access to care, quality …

This study aims to learn more about myelodysplastic syndromes (MDS) by following people with the condition for up to 20 years. Researchers will collect blood, bone marrow, and other samples to study how the disease progresses. The study does not test any new treatments but will h…

This study collects blood, bone marrow, skin, saliva, and stool samples from 1,000 healthy adults aged 18 and older. The samples are used as a comparison to better understand myelodysplastic syndromes (MDS), a group of blood stem cell disorders that can lead to cancer. Participan…

This study looks at whether measuring certain proteins in the blood (called cytokines) can help predict how patients with acute myeloid leukemia or related blood cancers will do on a milder type of chemotherapy. Researchers will collect blood samples from 60 adults before and dur…

This study looks at children with myelodysplastic syndromes (MDS) and juvenile myelomonocytic leukemia (JMML) to better understand these rare blood cancers. Researchers will carefully examine the shape of blood cells and search for genetic changes to improve how these diseases ar…

This study is collecting basic survival and complication information from 2000 people receiving stem cell transplants for blood cancers or immune diseases. The goal is to build a database that helps doctors and researchers better understand long-term outcomes and improve future t…

This study looks at whether a new whole genome test called ChromoSeq can find genetic changes in people with myelodysplastic syndrome (MDS) as well as current standard tests. About 60 adults with MDS or suspected MDS will take part. The goal is to see if ChromoSeq is reliable and…

This study looks at how anemia affects brain function, especially thinking and memory. Researchers will use a non-invasive light-based brain scan (fNIRS) to measure brain activity in 323 adults with different types of anemia. The goal is to find which brain areas are affected and…

This study looks at whether a new whole genome sequencing test called ChromoSeq can find more genetic changes in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) than current tests. Researchers will compare ChromoSeq results with standard genetic testing…